EVFM
Evofem Biosciences, Inc.
$0.006900
-1.43%
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 18, 2026
SEC
Evofem Biosciences reported Q1 2026 net sales of $0.9M (up from $0.8M YoY) but a net loss of $5.5M vs net income of $1.0
8-K — Impact 4/10
May 13, 2026
earnings_calendar
EVFM Q1 2026 Earnings Scheduled — 2026-05-13
Apr 30, 2026
SEC
Evofem entered into a 5-year exclusive distribution agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC
8-K — Impact 4/10
Mar 11, 2026
SEC
Analysis based on filing metadata only — document content was unavailable. The 8-K was filed for Items 2.02 (Results of
8-K — Impact 4/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Latest Reports
NEUTRAL
8-K
4/10
Evofem Biosciences reported Q1 2026 net sales of $0.9M (up from $0.8M YoY) but a net loss of $5.5M vs net income of $1.0
May 18, 2026
NEUTRAL
8-K
4/10
Evofem entered into a 5-year exclusive distribution agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC
Apr 30, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
4/10
Evofem Biosciences reported Q1 2026 net sales of $0.9M (up from $0.8M YoY) but a net loss of $5.5M v
May 18, 2026
NEUTRAL
8-K
4/10
Evofem entered into a 5-year exclusive distribution agreement with Clovis Davis Pharmaceuticals to c
Apr 30, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K was filed for Ite
Mar 11, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2024-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
EVFM Q1 2026 Earnings Scheduled — 2026-05-13
Mar 23, 2026
earnings_calendar
EVFM Q4 2025 Earnings Scheduled — 2026-03-23